FdaApplication
BLA 125389
Identifiers
- fda_app_no: BLA125389
Properties
| Property | Value |
|---|---|
| applicant_name | ADMA Biologics, Inc. |
| application_type | BLA |
| approval_date | 2012-12-19 |
Revenue by product
BIVIGAM
| Period | Revenue |
|---|---|
| Q2 2026 | $19.4M |
| Q1 2026 | $15.4M |
| Q2 2025 | $37.7M |
| Q1 2025 | $33.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BIVIGAM | — | 5GM/50ML | Injection |
| BIVIGAM | — | 10GM/100ML | Injection |
2 products